Stablepoint Partners LLC Has $1.31 Million Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Stablepoint Partners LLC grew its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 55.8% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 18,798 shares of the company's stock after buying an additional 6,730 shares during the quarter. Stablepoint Partners LLC's holdings in Novo Nordisk A/S were worth $1,305,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in the business. Bank of America Corp DE increased its position in shares of Novo Nordisk A/S by 8.1% during the 4th quarter. Bank of America Corp DE now owns 15,492,384 shares of the company's stock worth $1,332,655,000 after purchasing an additional 1,165,955 shares in the last quarter. GQG Partners LLC increased its position in shares of Novo Nordisk A/S by 74.7% during the 4th quarter. GQG Partners LLC now owns 12,994,533 shares of the company's stock worth $1,117,790,000 after purchasing an additional 5,556,460 shares in the last quarter. Loomis Sayles & Co. L P increased its position in shares of Novo Nordisk A/S by 34.2% during the 4th quarter. Loomis Sayles & Co. L P now owns 11,571,686 shares of the company's stock worth $995,397,000 after purchasing an additional 2,947,771 shares in the last quarter. Folketrygdfondet increased its position in shares of Novo Nordisk A/S by 0.5% during the 4th quarter. Folketrygdfondet now owns 8,903,938 shares of the company's stock worth $765,917,000 after purchasing an additional 40,313 shares in the last quarter. Finally, Renaissance Technologies LLC increased its position in shares of Novo Nordisk A/S by 1.5% during the 4th quarter. Renaissance Technologies LLC now owns 8,312,996 shares of the company's stock worth $715,084,000 after purchasing an additional 123,681 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on NVO. BMO Capital Markets reiterated a "market perform" rating and set a $64.00 target price (down previously from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Wall Street Zen lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Friday. Dbs Bank lowered shares of Novo Nordisk A/S to a "sell" rating in a report on Friday, April 25th. Hsbc Global Res raised shares of Novo Nordisk A/S to a "strong-buy" rating in a report on Monday, April 28th. Finally, Stifel Nicolaus lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Two analysts have rated the stock with a sell rating, six have issued a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $128.00.

Novo Nordisk A/S Trading Up 2.8%

Shares of NYSE NVO traded up $2.05 during mid-day trading on Friday, hitting $74.70. The company's stock had a trading volume of 9,535,540 shares, compared to its average volume of 6,905,079. The stock has a market cap of $335.22 billion, a price-to-earnings ratio of 22.71, a price-to-earnings-growth ratio of 0.90 and a beta of 0.66. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. Novo Nordisk A/S has a one year low of $57.00 and a one year high of $148.15. The company's fifty day simple moving average is $65.87 and its 200-day simple moving average is $80.54.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.92. The company had revenue of $11.87 billion for the quarter. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.